Merck Tbk (JK:MERK) — Market Cap & Net Worth
Market Cap & Net Worth: Merck Tbk (MERK)
Merck Tbk (JK:MERK) has a market capitalization of $95.29 Million (Rp1.63 Trillion) as of June 22, 2026. Listed on the JK stock exchange, this Indonesia-based company holds position #19435 globally and #324 in its home market, demonstrating a 0.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Merck Tbk's stock price Rp3630.00 by its total outstanding shares 448000000 (448.00 Million). Review Merck Tbk balance sheet liabilities to assess the company's total debt and financial obligations.
Merck Tbk Market Cap History: 2015 to 2026
Merck Tbk's market capitalization history from 2015 to 2026. Data shows growth from $80.26 Million to $95.29 Million (1.55% CAGR).
Index Memberships
Merck Tbk is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Jakarta Stock Exchange Composite Index
JKSE
|
$480.17 Billion | 0.02% | #316 of 864 |
Weight: Merck Tbk's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Merck Tbk Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Merck Tbk's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Merck Tbk's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Merck Tbk's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $80.26 Million | $983.45 Billion | $142.55 Billion | 0.00x | 0.00x |
| 2016 | $110.55 Million | $1.03 Trillion | $153.84 Billion | 0.00x | 0.00x |
| 2017 | $105.32 Million | $1.16 Trillion | $144.68 Billion | 0.00x | 0.00x |
| 2018 | $85.56 Million | $611.96 Billion | $1.16 Trillion | 0.00x | 0.00x |
| 2019 | $56.71 Million | $744.63 Billion | $78.26 Billion | 0.00x | 0.00x |
| 2020 | $67.78 Million | $655.85 Billion | $71.90 Billion | 0.00x | 0.00x |
| 2021 | $79.04 Million | $1.06 Trillion | $131.66 Billion | 0.00x | 0.00x |
| 2022 | $107.86 Million | $1.12 Trillion | $179.84 Billion | 0.00x | 0.00x |
| 2023 | $101.37 Million | $961.43 Billion | $178.24 Billion | 0.00x | 0.00x |
| 2024 | $94.50 Million | $1.04 Trillion | $153.46 Billion | 0.00x | 0.00x |
Competitor Companies of MERK by Market Capitalization
Companies near Merck Tbk in the global market cap rankings as of June 22, 2026.
Key companies related to Merck Tbk by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Merck Tbk Historical Marketcap From 2015 to 2026
Between 2015 and today, Merck Tbk's market cap moved from $80.26 Million to $ 95.29 Million, with a yearly change of 1.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rp95.29 Million | +8.36% |
| 2025 | Rp87.94 Million | -6.94% |
| 2024 | Rp94.50 Million | -6.77% |
| 2023 | Rp101.37 Million | -6.01% |
| 2022 | Rp107.86 Million | +36.45% |
| 2021 | Rp79.04 Million | +16.61% |
| 2020 | Rp67.78 Million | +19.53% |
| 2019 | Rp56.71 Million | -33.72% |
| 2018 | Rp85.56 Million | -18.76% |
| 2017 | Rp105.32 Million | -4.73% |
| 2016 | Rp110.55 Million | +37.74% |
| 2015 | Rp80.26 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Merck Tbk was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $95.29 Million USD |
| MoneyControl | $95.29 Million USD |
| MarketWatch | $95.29 Million USD |
| marketcap.company | $95.29 Million USD |
| Reuters | $95.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Merck Tbk
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research an… Read more